Spengler
Spengler
Listen to me
Our Tensonic Arm blood pressure monitor is the ideal instrument for practitioners who specialise in screening for high blood pressure but also for patients who need a very accurate self-diagnosis. Spengler is a partner of “DepistHTA”, the world’s largest high blood pressure screening campaign. This highly accurate instrument is also very easy to use, which is essential for patients in the screening and follow-up phases of treatment. Spengler excellence within everyone’s reach!
![Tensonic [EN]](https://www.spengler.fr/wp-content/uploads/2021/11/Tensonic-EN.jpg)
The new cuff covers both M and L sizes with a width of 22 to 42 cm. It can thus be adapted to the morphology of many patients. It is easy for practitioners to use on a daily basis, and an essential aide for family use in self-diagnosis. A size S cuff is also available as an option.
Thanks to the WHO tricolour indicator, the result obtained can be read in real time. No more questions needed. The diagnosis is reliable and precise, and can be shared immediately with your practitioner or your family and friends. The large backlit display is pleasant to read.
Family use of the Tensonic arm is possible thanks to its double memory of 60 time-stamped measurements. This makes it easy to switch from Patient 1 to Patient 2 mode without losing any of the previous self-diagnostics.
![Comaptible avec suivi HTA [EN]](https://www.spengler.fr/wp-content/uploads/2021/11/Comaptible-avec-suivi-HTA-EN.jpg)
The Tensonic Arm benefits from Spengler’s formidable expertise acquired over more than 110 years in measuring hypertension. It has been selected by the Hypertension Research Institute, a guarantee of excellence and reliability. Fully automatic, it’s not possible to use it wrongly. It’s also very reliable.
![Comaptible avec suivi HTA [EN]](https://www.spengler.fr/wp-content/uploads/2020/06/depisthta-512x480.png)
Discover DEPISTHTA. the Hypertension Research Foundation (FRHTA), a foundation recognized as a public utility, launched the DEPIST HTA application in September 2019. Why launch DEPISTHTA : the HTA affects more than 10 million French people, the declared rates of prevalences are largely underestimated: more than 50%...
Learn more
